Trial · NCT03421379
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia | Glucagon Nasal Powder | 100 | percentage of participants | ||
| Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia | Glucagon Hydrochloride Solution | 100 | percentage of participants | ||
| Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) | Glucagon Nasal Powder | 113 | Geometric Coefficient of Variation 32 | milligram/deciliter (mg/dL) | |
| Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) | Glucagon Hydrochloride Solution | 119 | Geometric Coefficient of Variation 33 | milligram/deciliter (mg/dL) | |
| PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Nasal Powder | 1.00 | Full Range 0.50 to 4.02 | hour | |
| PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Hydrochloride Solution | 1.50 | Full Range 0.67 to 4.00 | hour | |
| Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Nasal Powder | 4830 | Geometric Coefficient of Variation 89 | Picogram*hour/milliliter (pg*h/mL) | |
| Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Hydrochloride Solution | 3240 | Geometric Coefficient of Variation 32 | Picogram*hour/milliliter (pg*h/mL) | |
| PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Nasal Powder | 9520 | Geometric Coefficient of Variation 103 | picogram/milliliter (pg/mL) | |
| PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Hydrochloride Solution | 3290 | Geometric Coefficient of Variation 37 | picogram/milliliter (pg/mL) | |
| PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Nasal Powder | 0.25 | Full Range 0.17 to 0.67 | hour (h) | |
| PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM | Glucagon Hydrochloride Solution | 0.17 | Full Range 0.08 to 0.67 | hour (h) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03421379/results